New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
04:55 EDTLIFE, LIFE, LIFE, SI, SI, SI, BIOL, BIOL, BIOL, IVC, IVC, IVC, VAR, VAR, VAR, ARAY, ARAY, ARAY, CPHD, CPHD, CPHD, MASI, MASI, MASI, HRC, HRC, HRC, RHHBY, RHHBY, RHHBY, MCK, MCK, MCKWorldwide Business Research to host a conference
Field Service Medical Conference is being held in San Diego on February 19-21.
News For LIFE;RHHBY;HRC;MASI;CPHD;ARAY;VAR;IVC;BIOL;SI;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
05:15 EDTRHHBYGenentech reports ACE910 granted breakthrough therapy designation by FDA
Genentech, a member of the Roche Group, announced that the FDA has granted breakthrough therapy designation to ACE910 for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors. Hemophilia A, a rare genetic disorder, occurs when an essential blood clotting protein called factor VIII is either not present in sufficient amounts or is defective. People with severe hemophilia A can be susceptible to uncontrolled or difficult to control bleeding including internal bleeding, especially into the joints, which can lead to the need for joint replacements. Breakthrough therapy designation is designed to accelerate the development and review of medicines that demonstrate early clinical evidence of a substantial improvement over current treatment options for serious diseases. In a Phase I study, ACE910 showed promising results as a prophylactic treatment administered as a weekly subcutaneous injection in people with severe hemophilia A with and without inhibitors to factor VIII. The development of inhibitors is a serious complication of hemophilia A treatment regardless of disease severity, making it difficult, if not impossible, to achieve a level of factor VIII sufficient to control bleeding with traditional replacement therapies. Management of bleeding in people with hemophilia A who have inhibitors to factor VIII is a major challenge, and there remains a need for additional treatment options for these patients.
September 2, 2015
10:00 EDTCPHDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at H.C. Wainwright... Adobe (ADBE) initiated with a Perform at Oppenheimer... Antero Midstream (AM) initiated with a Buy at Ladenburg... Arbutus Biopharma (ABUS) initiated with an Outperform at JMP Securities... CSI Compressco (CCLP) initiated with a Market Perform at Wells Fargo... Cepheid (CPHD) initiated with an Equal Weight at Barclays... Cincinnati Financial (CINF) initiated with a Buy at MKM Partners... Disney (DIS) initiated with an Outperform at CLSA... Genomic Health (GHDX) initiated with an Underweight at Barclays... Green Brick (GRBK) initiated with a Neutral at Citi... Heron Therapeutics (HRTX) initiated with a Buy at BofA/Merrill... Karyopharm (KPTI) initiated with an Overweight at JPMorgan... PayPal (PYPL) initiated with a Buy at Argus... Quidel (QDEL) initiated with an Overweight at Barclays... Recro Pharma (REPH) initiated with a Buy at H.C. Wainwright.
09:17 EDTCPHDBarclays life science analysts hold an analyst/industry conference call
Subscribe for More Information
05:28 EDTCPHDCepheid initiated with an Equal Weight at Barclays
Subscribe for More Information
August 27, 2015
07:51 EDTRHHBYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 26, 2015
08:07 EDTMASIMasimo partners with St. Joseph Hoag Health to open wellness center
Subscribe for More Information
August 25, 2015
09:43 EDTCPHDCepheid issued warning letter from FDA following site inspection
Subscribe for More Information
August 24, 2015
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
08:29 EDTCPHDWilliam Blair to hold a field trip
Subscribe for More Information
August 23, 2015
12:35 EDTRHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
10:02 EDTVARHigh option volume stocks
High option volume stocks: XEO VAR AMCC XPO ROST INTU TFM BTE DXD
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
09:13 EDTARAYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Accuray (ARAY), up 12.7%... Brocade (BRCD), up 6%... salesforce.com (CRM), up 3.5%. DOWN AFTER EARNINGS: Intuit (INTU), down 6.7%... Deere (DE), down 5.4%... Nordson (NDSN), down 4.4%. ALSO LOWER: GigOptix (GIG), down 20% after 9.22M share Spot Secondary priced at $1.70... VirnetX Holding (VHC), down 19.8% after filing to sell 35M shares of common stock... Northwest Biotherapeutics (NWBO), down 8.7% after TheStreet's Adam Feuerstein reports, via Twitter, that CVax Phase 3 study has been temporarily halted in Germany.
06:01 EDTARAYAccuray awarded multi-system order by 21st Century Oncology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use